Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom
Pharmaceutical Technology
JUNE 12, 2023
A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has unanimously voted in support of Eisai and Biogen’s Leqembi and its clinical benefit in patients with early Alzheimer’s disease , raising the drug’s full approval prospects. Leqembi is the second drug developed by Biogen and Eisai for the treatment of Alzheimer’s disease.
Let's personalize your content